SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• SELLAS Life Sciences Group is set to announce its Q2 2025 earnings on Tuesday, August 12th, with analysts expecting a loss of ($0.08) per share.
• The company's stock increased by 2.8% to $1.64, with a market capitalization of approximately $163.14 million.
• Maxim Group recently raised the price target for SELLAS Life Sciences from $4.00 to $7.00 and assigned it a "buy" rating.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. On average, analysts expect SELLAS Life Sciences Group to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock traded down $0.02 during mid-day trading on Friday, reaching $1.58. The company's stock had a trading volume of 1,885,579 shares, compared to its average volume of 2,376,772. The company has a market cap of $157.65 million, a P/E ratio of -4.16 and a beta of 2.26. The firm's 50-day moving average is $1.78 and its two-hundred day moving average is $1.49. SELLAS Life Sciences Group has a 1-year low of $0.77 and a 1-year high of $2.27.

Analysts Set New Price Targets

Separately, Maxim Group boosted their target price on SELLAS Life Sciences Group from $4.00 to $7.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th.

Insider Buying and Selling at SELLAS Life Sciences Group

In other SELLAS Life Sciences Group news, Director Jane Wasman purchased 20,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were acquired at an average cost of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the director owned 30,400 shares of the company's stock, valued at $51,376. The trade was a 192.31% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On SELLAS Life Sciences Group

An institutional investor recently raised its position in SELLAS Life Sciences Group stock. Geode Capital Management LLC raised its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 168.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,200,428 shares of the company's stock after purchasing an additional 1,379,988 shares during the period. Geode Capital Management LLC owned 2.21% of SELLAS Life Sciences Group worth $4,819,000 at the end of the most recent reporting period. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.